Search research articles
Contact Us
Filters
Showing results (91-100 of 204) with videos related to
Page
of 21
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2021
A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer
Edward B Garon, Alexander I Spira, Melissa Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 16, 2026
Correction: cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution
Shuo Li, Weihua Zeng, Xiaohui Ni, et al.
The Oncologist
|
September 27, 2025
Characteristics of clinical trials associated with appeal and return on investment to participants: a review and framework
Maria J Fernandez Turizo, Maria A Velez, Beth Glenn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 23, 2023
Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study
Jürgen Wolf, Edward B Garon, Harry J M Groen, et al.
Radiology
|
December 13, 2017
Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung Cancer
Emily B Tsai, Kelsey Pomykala, Kathleen Ruchalski, et al.
Cancer Chemotherapy and Pharmacology
|
May 4, 2018
Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer
Egbert F Smit, Edward B Garon, Martin Reck, et al.
Cellular and Molecular Life Sciences : CMLS
|
June 13, 2012
Development of transcriptomic biomarker signature in human saliva to detect lung cancer
Lei Zhang, Hua Xiao, Hui Zhou, et al.
Cancer
|
December 24, 2015
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium
Conor E Steuer, Madhusmita Behera, Lynne Berry, et al.
Biomicrofluidics
|
December 24, 2015
High efficiency vortex trapping of circulating tumor cells
Manjima Dhar, Jessica Wong, Armin Karimi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer
Kazuhiko Nakagawa, Ernest Nadal, Edward B Garon, et al.
Page
of 21
Search research articles
Search
Showing results (91-100 of 204) with videos related to
Sort By:
Page
of 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2021
A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer
Edward B Garon, Alexander I Spira, Melissa Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 16, 2026
Correction: cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution
Shuo Li, Weihua Zeng, Xiaohui Ni, et al.
The Oncologist
|
September 27, 2025
Characteristics of clinical trials associated with appeal and return on investment to participants: a review and framework
Maria J Fernandez Turizo, Maria A Velez, Beth Glenn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 23, 2023
Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study
Jürgen Wolf, Edward B Garon, Harry J M Groen, et al.
Radiology
|
December 13, 2017
Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung Cancer
Emily B Tsai, Kelsey Pomykala, Kathleen Ruchalski, et al.
Cancer Chemotherapy and Pharmacology
|
May 4, 2018
Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer
Egbert F Smit, Edward B Garon, Martin Reck, et al.
Cellular and Molecular Life Sciences : CMLS
|
June 13, 2012
Development of transcriptomic biomarker signature in human saliva to detect lung cancer
Lei Zhang, Hua Xiao, Hui Zhou, et al.
Cancer
|
December 24, 2015
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium
Conor E Steuer, Madhusmita Behera, Lynne Berry, et al.
Biomicrofluidics
|
December 24, 2015
High efficiency vortex trapping of circulating tumor cells
Manjima Dhar, Jessica Wong, Armin Karimi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2021
RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer
Kazuhiko Nakagawa, Ernest Nadal, Edward B Garon, et al.
Page
of 21